Cigarette smoke-induced dysbiosis: comparative analysis of lung and intestinal microbiomes in COPD mice and patients.
Cigarette smoke
Emphysema
Inflammation
Intestine
Lung
Microbiome
Journal
Respiratory research
ISSN: 1465-993X
Titre abrégé: Respir Res
Pays: England
ID NLM: 101090633
Informations de publication
Date de publication:
10 May 2024
10 May 2024
Historique:
received:
03
01
2024
accepted:
04
05
2024
medline:
11
5
2024
pubmed:
11
5
2024
entrez:
10
5
2024
Statut:
epublish
Résumé
The impact of cigarette smoke (CS) on lung diseases and the role of microbiome dysbiosis in chronic obstructive pulmonary disease (COPD) have been previously reported; however, the relationships remain unclear. Our research examined the effects of 20-week cigarette smoke (CS) exposure on the lung and intestinal microbiomes in C57BL/6JNarl mice, alongside a comparison with COPD patients' intestinal microbiome data from a public dataset. The study found that CS exposure significantly decreased forced vital capacity (FVC), thickened airway walls, and induced emphysema. Increased lung damage was observed along with higher lung keratinocyte chemoattractant (KC) levels by CS exposure. Lung microbiome analysis revealed a rise in Actinobacteriota, while intestinal microbiome showed significant diversity changes, indicating dysbiosis. Principal coordinate analysis highlighted distinct intestinal microbiome compositions between control and CS-exposed groups. In the intestinal microbiome, notable decreases in Patescibacteria, Campilobacterota, Defferibacterota, Actinobacteriota, and Desulfobacterota were observed. We also identified correlations between lung function and dysbiosis in both lung and intestinal microbiomes. Lung interleukins, interferon-ɣ, KC, and 8-isoprostane levels were linked to lung microbiome dysbiosis. Notably, dysbiosis patterns in CS-exposed mice were similar to those in COPD patients, particularly of Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage 4 patients. This suggests a systemic impact of CS exposure. In summary, CS exposure induces significant dysbiosis in lung and intestinal microbiomes, correlating with lung function decline and injury. These results align with changes in COPD patients, underscoring the important role of microbiome in smoke-related lung diseases.
Sections du résumé
BACKGROUND
BACKGROUND
The impact of cigarette smoke (CS) on lung diseases and the role of microbiome dysbiosis in chronic obstructive pulmonary disease (COPD) have been previously reported; however, the relationships remain unclear.
METHODS
METHODS
Our research examined the effects of 20-week cigarette smoke (CS) exposure on the lung and intestinal microbiomes in C57BL/6JNarl mice, alongside a comparison with COPD patients' intestinal microbiome data from a public dataset.
RESULTS
RESULTS
The study found that CS exposure significantly decreased forced vital capacity (FVC), thickened airway walls, and induced emphysema. Increased lung damage was observed along with higher lung keratinocyte chemoattractant (KC) levels by CS exposure. Lung microbiome analysis revealed a rise in Actinobacteriota, while intestinal microbiome showed significant diversity changes, indicating dysbiosis. Principal coordinate analysis highlighted distinct intestinal microbiome compositions between control and CS-exposed groups. In the intestinal microbiome, notable decreases in Patescibacteria, Campilobacterota, Defferibacterota, Actinobacteriota, and Desulfobacterota were observed. We also identified correlations between lung function and dysbiosis in both lung and intestinal microbiomes. Lung interleukins, interferon-ɣ, KC, and 8-isoprostane levels were linked to lung microbiome dysbiosis. Notably, dysbiosis patterns in CS-exposed mice were similar to those in COPD patients, particularly of Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage 4 patients. This suggests a systemic impact of CS exposure.
CONCLUSION
CONCLUSIONS
In summary, CS exposure induces significant dysbiosis in lung and intestinal microbiomes, correlating with lung function decline and injury. These results align with changes in COPD patients, underscoring the important role of microbiome in smoke-related lung diseases.
Identifiants
pubmed: 38730440
doi: 10.1186/s12931-024-02836-9
pii: 10.1186/s12931-024-02836-9
doi:
Substances chimiques
Smoke
0
Types de publication
Journal Article
Comparative Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
204Subventions
Organisme : Ministry of Science and Technology, Taiwan
ID : 112-2314-B-038-013
Informations de copyright
© 2024. The Author(s).
Références
Gui X, Yang Z, Li MD. Effect of cigarette smoke on gut microbiota: state of knowledge. Front Physiol 2021;12.
Huxley RR, Woodward M. Cigarette smoking as a risk factor for coronary heart disease in women compared with men: a systematic review and meta-analysis of prospective cohort studies. Lancet. 2011;378:1297–305.
doi: 10.1016/S0140-6736(11)60781-2
pubmed: 21839503
Charbonnier J-P, Pompe E, Moore C, Humphries S, van Ginneken B, Make B, Regan E, Crapo JD, van Rikxoort EM, Lynch DA. Airway wall thickening on CT: relation to smoking status and severity of COPD. Respir Med. 2019;146:36–41.
doi: 10.1016/j.rmed.2018.11.014
pubmed: 30665516
Tian Z, Wu E, You J, Ma G, Jiang S, Liu Y, Hou J, Hou S, Ling Y, Pei L, Zheng X. Dynamic alterations in the lung microbiota in a rat model of lipopolysaccharide-induced acute lung injury. Sci Rep 2022;12.
Ramsheh MY, Haldar K, Esteve-Codina A, Purser LF, Richardson M, Müller-Quernheim J, Greulich T, Nowinski A, Barta I, Stendardo M, et al. Lung microbiome composition and bronchial epithelial gene expression in patients with COPD versus healthy individuals: a bacterial 16S rRNA gene sequencing and host transcriptomic analysis. Lancet Microbe. 2021;2:e300–10.
doi: 10.1016/S2666-5247(21)00035-5
pubmed: 35544166
Mayhew D, Devos N, Lambert C, Brown JR, Clarke SC, Kim VL, Magid-Slav M, Miller BE, Ostridge KK, Patel R, et al. Longitudinal profiling of the lung microbiome in the AERIS study demonstrates repeatability of bacterial and eosinophilic COPD exacerbations. Thorax. 2018;73:422–30.
doi: 10.1136/thoraxjnl-2017-210408
pubmed: 29386298
Dima E, Kyriakoudi A, Kaponi M, Vasileiadis I, Stamou P, Koutsoukou A, Koulouris NG, Rovina N. The lung microbiome dynamics between stability and exacerbation in chronic obstructive pulmonary disease (COPD): current perspectives. Respir Med. 2019;157:1–6.
doi: 10.1016/j.rmed.2019.08.012
pubmed: 31450162
Mammen MJ, Sethi S. COPD and the microbiome. Respirology. 2016;21:590–9.
doi: 10.1111/resp.12732
pubmed: 26852737
Healy C, Munoz-Wolf N, Strydom J, Faherty L, Williams NC, Kenny S, Donnelly SC, Cloonan SM. Nutritional immunity: the impact of metals on lung immune cells and the airway microbiome during chronic respiratory disease. Respir Res 2021;22.
Bowerman KL, Rehman SF, Vaughan A, Lachner N, Budden KF, Kim RY, Wood DLA, Gellatly SL, Shukla SD, Wood LG et al. Disease-associated gut microbiome and metabolome changes in patients with chronic obstructive pulmonary disease. Nat Commun 2020;11.
Huang C, Shi G. Smoking and microbiome in oral, airway, gut and some systemic diseases. J Translational Med 2019;17.
Wang L, Pelgrim CE, Peralta Marzal LN, Korver S, van Ark I, Leusink-Muis T, van Helvoort A, Keshavarzian A, Kraneveld AD, Garssen J, et al. Changes in intestinal homeostasis and immunity in a cigarette smoke- and LPS-induced murine model for COPD: the lung-gut axis. Am J Physiology-Lung Cell Mol Physiol. 2022;323:L266–80.
doi: 10.1152/ajplung.00486.2021
Chen X-Y, Chen Y-Y, Lin W, Chien C-W, Chen C-H, Wen Y-C, Hsiao T-C, Chuang H-C. Effects of Human umbilical cord-derived mesenchymal stem cells on the Acute cigarette smoke-Induced Pulmonary inflammation model. Front Physiol 2020;11.
Picherit C, Coxam V, Bennetau-Pelissero C, Kati-Coulibaly S, Davicco MJ, Lebecque P, Barlet JP. Daidzein is more efficient than genistein in preventing ovariectomy-induced bone loss in rats. J Nutr. 2000;130:1675–81.
doi: 10.1093/jn/130.7.1675
pubmed: 10867035
Liberti DC, Kremp MM, Liberti WA, Penkala IJ, Li S, Zhou S, Morrisey EE. Alveolar epithelial cell fate is maintained in a spatially restricted manner to promote lung regeneration after acute injury. Cell Rep 2021;35.
Chen L, Shan W, Liu P. Identification of concrete aggregates using K-means clustering and level set method. Structures. 2021;34:2069–76.
doi: 10.1016/j.istruc.2021.08.048
Subbian S, Allais L, Kumar S, Debusschere K, Verschuere S, Maes T, De Smet R, Conickx G, De Vos M, Laukens D et al. The effect of cigarette smoke exposure on the development of inflammation in lungs, gut and joints of TNF∆ARE mice. PLoS ONE 2015;10.
Laiman V, Lo Y-C, Chen H-C, Yuan T-H, Hsiao T-C, Chen J-K, Chang C-W, Lin T-C, Li S-J, Chen Y-Y et al. Effects of antibiotics and metals on lung and intestinal microbiome dysbiosis after sub-chronic lower-level exposure of air pollution in ageing rats. Ecotoxicol Environ Saf 2022;246.
Hoesterey D, Das N, Janssens W, Buhr RG, Martinez FJ, Cooper CB, Tashkin DP, Barjaktarevic I. Spirometric indices of early airflow impairment in individuals at risk of developing COPD: spirometry beyond FEV1/FVC. Respir Med. 2019;156:58–68.
doi: 10.1016/j.rmed.2019.08.004
pubmed: 31437649
pmcid: 6768077
Bhatt SP, Kim Y-i, Harrington KF, Hokanson JE, Lutz SM, Cho MH, DeMeo DL, Wells JM, Make BJ, Rennard SI, et al. Smoking duration alone provides stronger risk estimates of chronic obstructive pulmonary disease than pack-years. Thorax. 2018;73:414–21.
doi: 10.1136/thoraxjnl-2017-210722
pubmed: 29326298
Chen Z, Wang D, Liu X, Pei W, Li J, Cao Y, Zhang J, An Y, Nie J, Tong J. Oxidative DNA damage is involved in cigarette smoke-induced lung injury in rats. Environ Health Prev Med. 2015;20:318–24.
doi: 10.1007/s12199-015-0469-z
pubmed: 25967734
pmcid: 4550611
John G, Kohse K, Orasche J, Reda A, Schnelle-Kreis J, Zimmermann R, Schmid O, Eickelberg O, Yildirim Ali Ö. The composition of cigarette smoke determines inflammatory cell recruitment to the lung in COPD mouse models. Clin Sci. 2013;126:207–21.
doi: 10.1042/CS20130117
Liang G-B, He Z-H. Animal models of emphysema. Chin Med J. 2019;132:2465–75.
doi: 10.1097/CM9.0000000000000469
pubmed: 31567388
pmcid: 6831071
Crowley G, Kwon S, Caraher EJ, Haider SH, Lam R, Batra P, Melles D, Liu M, Nolan A. Quantitative lung morphology: semi-automated measurement of mean linear intercept. BMC Pulm Med 2019;19.
Pérez-Rial S, Girón-Martínez Á, Peces-Barba G. Modelos animales de enfermedad pulmonar obstructiva crónica. Arch Bronconeumol. 2015;51:121–7.
doi: 10.1016/j.arbres.2014.06.016
pubmed: 25201221
Fricker M, Deane A, Hansbro PM. Animal models of chronic obstructive pulmonary disease. Expert Opin Drug Discov. 2014;9:629–45.
doi: 10.1517/17460441.2014.909805
pubmed: 24754714
Adeloye D, Song P, Zhu Y, Campbell H, Sheikh A, Rudan I. Global, regional, and national prevalence of, and risk factors for, chronic obstructive pulmonary disease (COPD) in 2019: a systematic review and modelling analysis. Lancet Respiratory Med. 2022;10:447–58.
doi: 10.1016/S2213-2600(21)00511-7
Fehrenbach H, Tam A, Bates JHT, Churg A, Wright JL, Man SFP, Sin DD. Sex-related differences in pulmonary function following 6 months of cigarette exposure: implications for sexual dimorphism in mild COPD. PLoS ONE 2016;11.
Ghosh B, Chengala PP, Shah S, Chen D, Karnam V, Wilmsen K, Yeung-Luk B, Sidhaye VK. Cigarette smoke-induced injury induces distinct sex-specific transcriptional signatures in mice tracheal epithelial cells. Am J Physiology-Lung Cell Mol Physiol. 2023;325:L467–76.
doi: 10.1152/ajplung.00104.2023
Traini C, Nistri S, Calosi L, Vannucchi MG. Chronic exposure to cigarette smoke affects the Ileum and Colon of Guinea pigs differently. Relaxin (RLX-2, Serelaxin) prevents most local damage. Front Pharmacol 2022;12.
Lim D, Kim W, Lee C, Bae H, Kim J. Macrophage depletion protects against cigarette smoke-Induced Inflammatory response in the mouse Colon and lung. Front Physiol 2018;9.
Einarsson GG, Comer DM, McIlreavey L, Parkhill J, Ennis M, Tunney MM, Elborn JS. Community dynamics and the lower airway microbiota in stable chronic obstructive pulmonary disease, smokers and healthy non-smokers. Thorax. 2016;71:795–803.
doi: 10.1136/thoraxjnl-2015-207235
pubmed: 27146202
Sze MA, Dimitriu PA, Suzuki M, McDonough JE, Campbell JD, Brothers JF, Erb-Downward JR, Huffnagle GB, Hayashi S, Elliott WM, et al. Host Response to the lung Microbiome in Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2015;192:438–45.
doi: 10.1164/rccm.201502-0223OC
pubmed: 25945594
pmcid: 4595667
Haldar K, George L, Wang Z, Mistry V, Ramsheh MY, Free RC, John C, Reeve NF, Miller BE, Tal-Singer R et al. The sputum microbiome is distinct between COPD and health, independent of smoking history. Respir Res 2020;21.
Lee SH, Yun Y, Kim SJ, Lee E-J, Chang Y, Ryu S, Shin H, Kim H-L, Kim H-N, Lee JH. Association between cigarette smoking status and composition of Gut Microbiota: Population-based cross-sectional study. J Clin Med 2018;7.
Allais L, Kerckhof FM, Verschuere S, Bracke KR, De Smet R, Laukens D, Van den Abbeele P, De Vos M, Boon N, Brusselle GG, et al. Chronic cigarette smoke exposure induces microbial and inflammatory shifts and mucin changes in the murine gut. Environ Microbiol. 2015;18:1352–63.
doi: 10.1111/1462-2920.12934
pubmed: 26033517
Dolma K, Freeman AE, Rezonzew G, Payne GA, Xu X, Jilling T, Blalock JE, Gaggar A, Ambalavanan N, Lal CV. Effects of hyperoxia on alveolar and pulmonary vascular development in germ-free mice. Am J Physiology-Lung Cell Mol Physiol. 2020;318:L421–8.
doi: 10.1152/ajplung.00316.2019
Rangelov K, Sethi S. Role of infections. Clin Chest Med. 2014;35:87–100.
doi: 10.1016/j.ccm.2013.09.012
pubmed: 24507839
pmcid: 7115722
Zhang D, Li S, Wang N, Tan H-Y, Zhang Z, Feng Y. The cross-talk between gut microbiota and lungs in Common Lung diseases. Front Microbiol 2020;11.
Li N, Dai Z, Wang Z, Deng Z, Zhang J, Pu J, Cao W, Pan T, Zhou Y, Yang Z et al. Gut microbiota dysbiosis contributes to the development of chronic obstructive pulmonary disease. Respir Res 2021;22.
O’Dwyer DN, Ashley SL, Gurczynski SJ, Xia M, Wilke C, Falkowski NR, Norman KC, Arnold KB, Huffnagle GB, Salisbury ML, et al. Lung microbiota contribute to pulmonary inflammation and Disease Progression in Pulmonary Fibrosis. Am J Respir Crit Care Med. 2019;199:1127–38.
doi: 10.1164/rccm.201809-1650OC
pubmed: 30789747
pmcid: 6515865
Bernard-Raichon L, Venzon M, Klein J, Axelrad JE, Zhang C, Sullivan AP, Hussey GA, Casanovas-Massana A, Noval MG, Valero-Jimenez AM et al. Gut microbiome dysbiosis in antibiotic-treated COVID-19 patients is associated with microbial translocation and bacteremia. Nat Commun 2022;13.
Liu Y, Teo SM, Méric G, Tang HHF, Zhu Q, Sanders JG, Vázquez-Baeza Y, Verspoor K, Vartiainen VA, Jousilahti P, et al. The gut microbiome is a significant risk factor for future chronic lung disease. J Allergy Clin Immunol. 2023;151:943–52.
doi: 10.1016/j.jaci.2022.12.810
pubmed: 36587850
pmcid: 10109092
Singanayagam A, Chiu Y-C, Lee S-W, Liu C-W, Lin RC-J, Huang Y-C, Lan T-Y, Wu LS-H. Comprehensive profiling of the gut microbiota in patients with chronic obstructive pulmonary disease of varying severity. PLoS ONE 2021;16.